A detailed history of Core Cap Advisors, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Core Cap Advisors, LLC holds 152 shares of ALNY stock, worth $68,272. This represents 0.0% of its overall portfolio holdings.

Number of Shares
152
Previous 380 60.0%
Holding current value
$68,272
Previous $173,000 60.69%
% of portfolio
0.0%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2025

Jan 13, 2026

SELL
$423.47 - $491.22 $96,551 - $111,998
-228 Reduced 60.0%
152 $68,000
Q3 2025

Oct 22, 2025

BUY
$311.12 - $482.13 $117,603 - $182,245
378 Added 18900.0%
380 $173,000
Q1 2025

May 09, 2025

BUY
$233.07 - $290.7 $466 - $581
2 New
2 $0
Q2 2024

Aug 08, 2024

BUY
$143.31 - $247.0 $286 - $494
2 New
2 $0
Q4 2022

Feb 10, 2023

BUY
$185.53 - $241.31 $371 - $482
2 New
2 $0

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $55.3B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Core Cap Advisors, LLC Portfolio

Follow Core Cap Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Core Cap Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Core Cap Advisors, LLC with notifications on news.